| Acumen Pharmaceuticals is engaged in the discovery and development of targeted therapies for the treatment of Alzheimer's disease ("AD"). Co.'s lead drug candidate, ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, has demonstrated functional and protective effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic models for ADs. Co. and Merck & Co. discovered and developed ACU193 through an eight-year research collaboration. Co. holds exclusive rights to the program. Co. submitted an Investigation Drug Application for ACU193 to the Food and Drug Administration. The ABOS YTD return is shown above.
The YTD Return on the ABOS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ABOS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABOS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.